The online version of this article (doi:10.1007/s00262-014-1540-0) contains supplementary material, which is available to authorized users.
Malignant melanoma is the most aggressive and deadliest form of skin cancer due to its highly metastatic potential, which calls for new and improved therapies. Cationic antimicrobial peptides (CAPs) are naturally occurring molecules found in most species, in which they play a significant role in the first line of defense against pathogens, and several CAPs have shown promising potential as novel anticancer agents. Structure–activity relationship studies on the CAP bovine lactoferricin allowed us to de novo design short chemically modified lytic anticancer peptides. In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice. Intratumoral administration of LTX-315 resulted in tumor necrosis and the infiltration of immune cells into the tumor parenchyma followed by complete regression of the tumor in the majority of the animals. LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1β, IL6 and IL18 in vivo. Animals cured by LTX-315 treatment were protected against a re-challenge with live B16 tumor cells both intradermally and intravenously. Together, our data indicate that intratumoral treatment with LTX-315 can provide local tumor control followed by protective immune responses and has potential as a new immunotherapeutic agent.
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648 PubMed
Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ (1991) Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51:3062–3066 PubMed
Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW et al (1998) The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102:1662–1673. doi: 10.1172/JCI4105 PubMedCentralPubMedCrossRef
Domagala W, Koss L (1980) Surface configuration of human tumor cells obtained by fine needle aspiration biopsy. Scan Electron Microsc 3:101–108 PubMed
Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB (2000) In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15:151–160 PubMed
Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH et al (2002) Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 22:2703–2710 PubMed
Overwijk WW, Restifo NP (2001) B16 as a mouse model for human melanoma. Current PROTOCOLS IN IMMUNOLOGY. Wiley, New York, pp 1–32
Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR et al (1999) A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5:1629–1637 PubMed
- Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
Ketil André Camilio
Chandra Sekhar Ravuri
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II